(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 April 2015- Actelion Ltd (SIX: ATLN) today announced its results for the first quarter of 2015. OPERATING HIGHLIGHTS Opsumit (macitentan) - Q1 2015 sales of CHF 95 million Opsumit (macitentan) - approved in Japan in March 2015 Selexipag (Uptravi) - GRIPHON data presented at American College of Cardiology Selexipag (Uptravi) - FDA, EMA regulatory procedures on track Specialty franchise - Immunology portfolio advances FINANCIAL HIGHLIGHTS Product sales of CHF 515 million - strong growth driven by Opsumit uptake Core earnings of CHF 218 million - increased operational leverage Core EPS of CHF 1.61 - delivering value to shareholders Strong...
↧